- 专利标题： Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor
-
申请号： US16471679申请日： 2017-12-18
-
公开(公告)号： US11319298B2公开(公告)日： 2022-05-03
- 发明人: Jianming Bao , Ronald Ferguson , Xiaolei Gao , Scott Harrison , Sandra L. Knowles , Michael Man-Chu Lo , Robert D. Mazzola, Jr. , Jeffrey W. Shubert
- 申请人： Merck Sharp & Dohme Corp. , MSD R&D (China) Co., Ltd.
- 申请人地址： US NJ Rahway; CN Shanghai
- 专利权人： Merck Sharp & Dohme Corp.,MSD R&D (China) Co., Ltd.
- 当前专利权人： Merck Sharp & Dohme Corp.,MSD R&D (China) Co., Ltd.
- 当前专利权人地址： US NJ Rahway; CN Shanghai
- 代理商 Eric A. Meade; John C. Todaro
- 优先权： WOPCT/CN2016/111530 20161222
- 国际申请： PCT/US2017/066917 WO 20171218
- 国际公布： WO2018/118734 WO 20180628
- 主分类号： C07D401/02
- IPC分类号： C07D401/02 ; C07D401/04 ; C07D401/14 ; C07D405/14 ; C07D413/14 ; C07D417/14 ; C07D491/107 ; C07D498/08 ; C07D513/04
摘要：
The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
公开/授权文献
信息查询
